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journal homepage: www.elsevier.com/locate/surgLetters to the EditorThe role of proportionate kinetic growth rate fraction
in future remnant liver function over volume
determined by 99mTc-Mebrofenin hepatobiliary
scintigraphy including SPECT and computed
tomography in the risk prediction of postoperative
mortality in ALPPSWe would like to propose a potential novel method for predict-
ing posthepatectomy liver failure (PHLF) after associating liver par-
titioning and portal vein ligation for staged hepatectomy (ALPPS).
This technique uses the combined results of future remnant liver
volume (fRLV)1,2 based on volumetric computed tomography (CT)
measurements and future remnant liver function (fRLF) based on
technetium-99m (99mTc)-Mebrofenin hepatobiliary scintigraphy
(HBS) with a Single Photon Emission Computed Tomography
(SPECT) camera.3e6 Individually, the standard analysis of these pre-
operative assessments have shown shortcomings in predicting
PHLF in the interstage of ALPPS.7e10 But, by using the results in
combination, we suggest a new integrated parameter: the relative
proportion kinetic growth rate (KGR) fraction of functional over
volume increase that might prove to be better at predicting PHLF
at the interstage of ALPPS.
In 5 patients (48e57 years of age) who underwent the hybrid
ALPPS procedure11,12 for hepaticmalignancy (2 intrahepatic cholan-
giocarcinoma, 1 colorectal liver metastasis, 1 gallbladder cancer,
and 1 hepatocellular carcinoma), fRLVmeasurements by volumetric
CT and fRLF assessment by HBS scan5 were performed both preop-
eratively and during the interstage ALPPS. The decision to proceed
to completion hepatectomy was performed if the predefined crit-
ical cutoff levels of both fRLV (>30%) and fRLF (>2.7%/min/m2)
were met.
All patients had an insufficient fRLV (mean 22%; 10%e28.9%)
preoperatively. The preoperative mean fRLF was 2.6 %/min/m2
(range: 0.9%e3.5 %/min/m2). At the interstage, the fRLV increased
in all patients, showing a mean 98% increase after a mean interval
of 10.4 days after completion of the first step (7e14 days). However,
all, but 1 patient, had a fRLF growth with a mean 49% increase
measured at a mean interval of 10.6 days (8e28 days; Table 1).
The patient without fRLF growth did not proceed to completionTable 1
Preoperative and interstage volumetric and HBS results with calculated









Patient 1 22.1 45.0 3.5
Patient 2 9.9 31.6 2.7
Patient 3 28.7 40.4 3.3
Patient 4 24.5 52.0 2.8
Patient 5 25.5 28.8 (42.1*) 0.9
Mean 22.1 39.6 2.6
* 28 days after PVE.hepatectomy. The remaining patients underwent completion hep-
atectomy. In 1 of these 4 remaining patients, completion hepatec-
tomy had been postponed to 28 days after liver partitioning
owing to an initially insufficient fRLF, but this patient developed le-
thal PHLF on postop day 4. The clinical course of this patient further
demonstrates the drawbacks of using absolute cutoff values of fRLV
or fRLF as described elsewhere7,9,10, and the alleged importance of
using KGR in clinical context as a better predictor for PHLF.13e16
The “disproportionate” increase of the remnant liver volume
compared to fRLF might be the cause of the greater morbidity
and mortality reported in ALPPS.7 In addition, recent pathologic
studies of the remnant liver showing a higher density but smaller
hepatocytes in the remnant liver seem to support the dysfunctional
volume theory. These hepatocytes also contain fewer organelles
and are thus less metabolic active.17 This intangible relationship
has led us to recommend the increase over time of function relative
to volume (proportionate KGR function over volume fraction [pKGR
f/V]) as a predictor for PHLF.
pKGR f=V ¼
0









We encourage further research to validate the ideal cutoff value
of proportionate KGR function over volume fraction in larger series.
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0039-6060/© 2018 Elsevier Inc. All rights reserved.Familial nonmedullary thyroid cancer: When the data
and conclusions do not matchTo the Editors:
When reading the paper by El Lakis et al.1 on familial nonmedul-
lary thyroid cancer (FNMTC), it seems their conclusions contradict
their data.
The greater number of lymphnodemetastases (LNMs) in FNMTC
patients reported by El Lakis et al.1 were foundmostly in the central
compartment; however, it is well recognized how common and
clinically irrelevant these types of nodal metastases prove to be.
Moreover, because total thyroidectomy was performed in FNMTC
more frequently than in the Surveillance, Epidemiology, and End
Results (SEER) patients (98.2% vs 84%, respectively), and because
more extensive surgery could prompt more neck exploration and
subsequentlymore central neck dissections, a greater rate of central
LNMs in FNMTC patients could, in fact, represent a bias of the study.
Similarly, the difference in the female-to-male ratios among groups,
with more males included in the FNMTC group, could be another
possible bias. Of note, the SEER group patients presented with a
more aggressive histopathology, with almost twice as many tall
cell and follicular thyroid cancer (TC/FTC) variants.
Separating the patients presenting with clinical disease from
thosediscoveredbyscreening isquite arbitrary.Most thyroidnodules
today fall within the category of incidental findings, and it is unclear
what definition of clinical disease the authors applied. Of interest, the
20patientsdetectedbyscreeningpatientswithFNMTCshowedmore
favorable features and had fewer total thyroidectomies performed
than the SEER patients (84.2% vs 98.2%). However, after excluding
the screening group, there was little difference regarding age, TC/
FTC types, extrathyroidal extension, and number of patients with
T1 stage and lateral LNMs between FNMTC and the SEER patients.
Moreover, the FNMTC patients with > 2 affected relatives had a
similar number of lateral LNMs and 3 times less TC/FTC variants.
Considering that recurrence-risk stratificationwas not applied, a
recurrence rate of 12.8% in the FNMTC group falls within the widely
accepted lower range for sporadic NMTC. Although patients in the
SEER group were registered from 1998 to 2007, we do not know the
period for the FNMTC patients. Nevertheless, the mean follow-up
for the FNMTC patients was 220 ± 416 months (18 ± 35 years)
compared with 70 ± 58 months (5.8 ± 4.8 years) in the SEER group.
In such a timespan, the field of thyroid cancer has changed so much
(American Thyroid Association risk stratification; response to initial
treatment assessment; Tumor, Node, and Metastasis 8th edition,
etc) that assessment and definition of recurrent disease would be
very different today.
